Used when the target dose translates to fewer than 50 units on the syringe, improving accuracy by spreading the graduation marks across the full barrel
Tirabassi G, Muscogiuri G, Colao A, Balercia G
Dihydroergotamine has also been shown to be an inhibitor of cytochrome P450 3A catalyzed reactions and rare reports of ergotism have been obtained from patients treated with dihydroergotamine and macrolide antibiotics (e.g., troleandomycin, clarithromycin, erythromycin), and in patients treated with dihydroergotamine and protease inhibitors (e.g., ritonavir), presumably due to inhibition of cytochrome P450 3A metabolism of ergotamine (see CONTRAINDICATIONS)
Common, mild side effects: Pain, redness, or itching at the injection site Mild nausea or diarrhea Headache Temporary dizziness Rare but more serious reactions: Allergic reactions (rash, swelling, breathing difficulty) Heart palpitations Low potassium levels during rapid correction of severe deficiency Very rare cases of anaphylaxis requiring emergency care Seek medical attention immediately if you experience symptoms of a serious allergic reaction
